(FDA MedWatch definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * requires intervention to prevent permanent impairment or damage A 59-year-old woman developed tumour lysis syndrome (TLS) during treatment with carboplatin and ...
When DOCIVYX was combined with carboplatin for the treatment of chemotherapy-naive, advanced non-small cell lung carcinoma, patients 65 years of age or greater (28%) experienced higher frequency of infection compared to similar patients treated with DOCIVYX+cisplatin, and a higher frequency of di...
neutrophils <500 cells/mm3for more than 1 week, or severe or cumulative cutaneous reactions during DOCETAXEL INJECTION therapy should have the dosage adjusted from 100 mg/m2to 75 mg/m2. If the patient continues to experience these reactions, the dosage should either be decreased from 75 mg...
AR-targeted therapy: abiraterone, enzalutamide; chemotherapy: cabazitaxel, carboplatin, docetaxel, doxorubicin, estramustine, ketoconazole; immunotherapy: bavituximab, DCVAC, PROSTVAC, TroVax; kinase inhibitors: AZD5363, BKM120, cabozantinib, ribociclib, temsirolimus; other: ascorbic acid, ciproflaxin, ...
Phase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian can... The purpose of this study was to assess the response rate, toxicity, progression-free survival, and overall survival in a series of p...
When administered as sequential infusions, taxane derivatives should be administered before platinum derivatives (cisplatin, carboplatin) to limit myelosuppression and to enhance efficacy Storage Unused vials: Store at 2-25°C (36-77°F) Opened multi-use vials: Store at 2-8°C (36-46°F) and ...
Anaplastic thyroid cancer:According to the American Thyroid Association guidelines for anaplastic thyroid cancer, the use of cytotoxic chemotherapy involving a taxane (docetaxel or paclitaxel), administered with or without anthracyclines (doxorubicin) or platinum-based agents (cisplatin or carboplatin), is ...
A semisynthetic relative of paclitaxel, which has been FDA-approved for second-line treatment of NSCLC, and has been studied as a doublet with carboplatin and cisplatin as well as in first-line treatment. Docetaxel has twofold greater affinity for the binding site on the beta-tubulin subunit as...
Docetaxel can cause severe side effects including death, especially if you receive high doses, if you have liver disease, or if you have non-small cell lung cancer and you have been treated in the past with chemotherapy that contains platinum (cisplatin, carboplatin, oxaliplatin)....
Giannakakis T, Ziras N, Kakolyris S, Mavroudis D, Androulakis N, Agelaki S et al (2000) Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicentre phase I study. Eur J Cancer 36:742–747 doi:10.1016/S0959-8049(00)00005-8 Art...